Study of Adjuvant Nimotuzumab Combined with Nab-paclitaxel+ Gemcitabine in EGFR-positive Pancreatic Cancer

NCT06722911 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

57

Enrollment

OTHER

Sponsor class

Conditions

Pancreatic Cancer Resectable

Interventions

DRUG: Nimotuzumab
DRUG: AG

Sponsor

Zhejiang Provincial People's Hospital